Virtu Financial’s ABVC BioPharma ABVC Stock Holding History

Virtu Financial’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,935	Closed	-$9K	–	1283
2024 Q4	$9K	Buy	+15,935	New	+$8.89K	﹤0.01%	1389
2023 Q4	–	Sell	-20,265	Closed	-$21K	–	1518
2023 Q3	$21K	Buy	+20,265	New	+$49K	﹤0.01%	1007
2022 Q1	–	Sell	-2,722	Closed	-$92K	–	1439
2021 Q4	$92K	Buy	2,722 +1,333	+96%	+$41.8K	0.01%	1165
2021 Q3	$32K	Buy	+1,389	New	+$39.3K	﹤0.01%	1335

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtu Financial's ABVC Position: Q1 2025 in Review

Virtu Financial sold out of ABVC BioPharma (ABVC) in Q1 2025, closing a stake of 15,935 shares — an estimated $9K sold.

Virtu Financial first reported a position in ABVC in Q3 2021 and held it in 4 quarters. The position peaked at $92K in Q4 2021. 10 funds tracked by Wall St. Rank hold ABVC as of Q1 2025.

Virtu Financial reported no remaining ABVC BioPharma position as of Q1 2025 after selling out during the quarter.
Virtu Financial sold 15,935 ABVC BioPharma shares in Q1 2025, an estimated $9K.
Virtu Financial first reported a position in ABVC BioPharma in Q3 2021 and held it in 4 quarters.
Virtu Financial's ABVC BioPharma position peaked at $92K in Q4 2021.
10 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.